Immunome (NASDAQ:IMNM) Sets New 12-Month High – Should You Buy?

Immunome, Inc. (NASDAQ:IMNM)’s share price reached a new 52-week high on Wednesday . The company traded as high as $28.84 and last traded at $29.00, with a volume of 267207 shares trading hands. The stock had previously closed at $27.56.

Wall Street Analyst Weigh In

Several research firms recently issued reports on IMNM. Citigroup reiterated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners cut their price objective on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Truist Financial boosted their target price on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a research report on Thursday, July 9th. Finally, Wall Street Zen cut shares of Immunome from a “sell” rating to a “strong sell” rating in a research note on Saturday. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.64.

Immunome Price Performance

The business has a 50-day simple moving average of $22.56 and a two-hundred day simple moving average of $22.25. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of -11.65 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). As a group, equities analysts anticipate that Immunome, Inc. will post -2.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunome

In other news, Director Isaac Barchas sold 11,048 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $27.25, for a total value of $301,058.00. Following the transaction, the director directly owned 92,211 shares of the company’s stock, valued at $2,512,749.75. This represents a 10.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total transaction of $1,244,100.00. Following the sale, the insider owned 15,805 shares of the company’s stock, valued at approximately $357,509.10. This represents a 77.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 682,310 shares of company stock valued at $15,675,566 in the last quarter. 7.21% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Creative Planning grew its position in shares of Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Immunome by 14.4% in the fourth quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock valued at $159,000 after buying an additional 935 shares in the last quarter. Allworth Financial LP acquired a new stake in shares of Immunome in the second quarter valued at approximately $25,000. California State Teachers Retirement System boosted its stake in shares of Immunome by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock valued at $1,439,000 after buying an additional 1,167 shares during the period. Finally, Assetmark Inc. boosted its stake in shares of Immunome by 46.6% in the first quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock valued at $99,000 after buying an additional 1,442 shares during the period. 44.58% of the stock is owned by institutional investors.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.